BioCentury
ARTICLE | Clinical News

Aldeyra's allergic conjunctivitis therapy clears Phase III hurdle

March 26, 2019 1:46 PM UTC

Aldeyra shares rose $2.57 (36%) to $9.71 on Tuesday after the company said both doses of reproxalap (ADX-102) met the primary endpoint in the Phase III ALLEVIATE trial to treat allergic conjunctivitis. The small molecule covalently binds and traps free aldehydes.

The 318-patient trial's primary endpoint evaluated ocular itch score from 10 to 60 minutes after allergen challenge, as assessed by area under the curve on a scale of 0-4. Compared with vehicle, the 0.25% and 0.5% doses of reproxalap topical ophthalmic solution led to significant reductions in ocular itching (p<0.0001 and p=0.0025, respectively)...

BCIQ Company Profiles

Aldeyra Therapeutics Inc.